Trials / Completed
CompletedNCT01252563
Amlodipine 10mg Drug Use Investigation
NORVASC10MG DRUG USE INVESTIGATION
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 14,141 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
In this survey, to collect the safety and efficacy information in the subjects who have been treated with amlodipine 5mg at least 4 weeks in daily practice.
Detailed description
All the subjects whom an investigator prescribes Amlodipine (Norvasc®) 10mg Tablet should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine | Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2010-12-03
- Last updated
- 2021-01-28
- Results posted
- 2019-04-02
Source: ClinicalTrials.gov record NCT01252563. Inclusion in this directory is not an endorsement.